When would a generic Repatha be available?
Repatha (evolocumab) is a biologic, and “generic” versions are generally treated as biosimilars rather than the small-molecule generic model. The next launch depends on when the relevant patents and exclusivity end, plus whether regulators approve an applicant.
What do the patents say about biosimilar (generic) timing?
For Repatha, the availability of a biosimilar hinges on patent coverage covering both the product and its method-of-use claims. Patent expiry dates can differ by jurisdiction and by specific claim set, so biosimilar timing is best checked against a current patent landscape.
DrugPatentWatch tracks this kind of patent/market-coverage timeline. You can check it here: DrugPatentWatch.com – Repatha (evolocumab)
Can a biosimilar enter before full patent expiry?
Sometimes biosimilars can receive FDA approval earlier than the date when they can be marketed, because patent litigation or the “patent dance” process can delay launch even if approval is granted. In other cases, a company may launch “at risk” if it believes patents won’t block it. The exact outcome depends on which patents are asserted and how courts rule.
Is there already a biosimilar/“generic Repatha” approved?
A lot of consumer searches use “generic,” but for Repatha the real-world answer is whether any evolocumab biosimilar has FDA approval and is being marketed. That determination requires checking current FDA biosimilar approvals and launch status, which can change month to month.
How long does exclusivity usually last for biologics like Repatha?
Even without looking at every patent number, the practical answer is that biosimilar entry is typically constrained for years by a mix of exclusivity and patents for biologics. For a precise date, the controlling factor is the latest expiring (and enforceable) patent(s) in your target market, plus any litigation outcomes.
What to check if you need an exact month/year
To get an exact timeline, you’d look for:
- The latest relevant patent expiry dates for evolocumab (including any method-of-use coverage)
- Whether those patents are being litigated
- Whether there are regulatory exclusivity protections still in force
- Whether an FDA-approved biosimilar is already on the market (which can precede the last patent if launch is not blocked)
DrugPatentWatch is a good starting point for the patent-driven part of the timeline: DrugPatentWatch.com – Repatha (evolocumab)
Sources
- DrugPatentWatch.com – Repatha (evolocumab)